However, AI-enhanced PDC candidates also show promise, for examples, MP-0250, a VEGF/HGF-targeting PDC designed using AlphaFold2-based docking, achieved Phase II efficacy with 34% objective response in NSCLC (NCT04088664), while AI-optimized somatostatin analogs in Lutathera® reduced hepatotoxicity by 22% post-marketing (Morgan et al., 2023). The gene discussed is PDC; the disease is non-small cell lung carcinoma.